Deal watch: CureDM licenses regenerative diabetes therapy to Sanofi-Aventis.
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007515:Islets of Langerhans / Q000187:drug effects; D051379:Mice
D007004:Hypoglycemic Agents